These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38476752)

  • 21. Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods and Input Data.
    Treskova M; Pozo-Martin F; Scholz S; Schönfeld V; Wichmann O; Harder T
    Pharmacoeconomics; 2021 Mar; 39(3):287-315. PubMed ID: 33462760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands.
    Meijboom MJ; Rozenbaum MH; Benedictus A; Luytjes W; Kneyber MC; Wilschut JC; Hak E; Postma MJ
    Vaccine; 2012 Jun; 30(31):4691-700. PubMed ID: 22561315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study.
    Ares-Gómez S; Mallah N; Santiago-Pérez MI; Pardo-Seco J; Pérez-Martínez O; Otero-Barrós MT; Suárez-Gaiche N; Kramer R; Jin J; Platero-Alonso L; Alvárez-Gil RM; Ces-Ozores OM; Nartallo-Penas V; Mirás-Carballal S; Piñeiro-Sotelo M; Malvar-Pintos A; González-Pérez JM; Rodríguez-Tenreiro-Sánchez C; Rivero-Calle I; Salas A; Durán-Parrondo C; Martinón-Torres F;
    Lancet Infect Dis; 2024 Aug; 24(8):817-828. PubMed ID: 38701823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of nirsevimab on hospitalisations for respiratory syncytial virus bronchiolitis in France, 2023-24: a modelling study.
    Brault A; Pontais I; Enouf V; Debeuret C; Bloch E; Paireau J; Rameix-Welti MA; White M; Baudemont G; Lina B; Parent du Châtelet I; Casalegno JS; Vaux S; Cauchemez S
    Lancet Child Adolesc Health; 2024 Oct; 8(10):721-729. PubMed ID: 39208833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact and cost-effectiveness of strategies to prevent respiratory syncytial virus (RSV) disease in Vietnam: A modelling study.
    Do LAH; Le NTN; Mahmud S; Mulholland K; Pecenka C; Clark A
    Vaccine; 2023 Nov; 41(46):6782-6790. PubMed ID: 37690873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modeling the optimal seasonal monoclonal antibody administration strategy for respiratory syncytial virus (RSV) prevention based on age-season specific hospitalization rate of RSV in Suzhou, China, 2016-2022.
    Ren S; Chen Q; Zhang Y; Yi L; Qian C; Lu Y; Shen J; Liu X; Jiang M; Wang B; Song J; Shao X; Zhang T; Tian J; Zhao G
    Vaccine; 2024 Jan; 42(2):352-361. PubMed ID: 38057209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modelling the household-level impact of a maternal respiratory syncytial virus (RSV) vaccine in a high-income setting.
    Campbell PT; Geard N; Hogan AB
    BMC Med; 2020 Nov; 18(1):319. PubMed ID: 33176774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-Effectiveness Analysis of Maternal Respiratory Syncytial Virus Vaccine in Protecting Infants from RSV Infection in Japan.
    Ishiwada N; Akaishi R; Kobayashi Y; Togo K; Yonemoto N; Matsuo M; Kaneko S; Law AW; Kamei K
    Infect Dis Ther; 2024 Jul; 13(7):1665-1682. PubMed ID: 38834858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimizing next-generation RSV prevention in Mali: A cost-effectiveness analysis of pediatric vaccination, maternal vaccination, and extended half-life monoclonal antibody immunoprophylaxis.
    Laufer RS; Baral R; Buchwald AG; Campbell JD; Coulibaly F; Diallo F; Doumbia M; Driscoll AJ; Galvani AP; Keita AM; Neuzil KM; Sow S; Pecenka C; Ortiz JR; Fitzpatrick MC
    PLOS Glob Public Health; 2023; 3(5):e0001432. PubMed ID: 37145993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A latent class analysis of factors influencing preferences for infant respiratory syncytial virus (RSV) preventives among pregnant people in the United States.
    Maculaitis MC; Hauber B; Beusterien KM; Will O; Kopenhafer L; Law AW; Vietri JT; Cappelleri JC; Coulter JR; Pugh S; Shea KM
    Hum Vaccin Immunother; 2024 Dec; 20(1):2358566. PubMed ID: 38847198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of mass paediatric influenza vaccination on existing influenza vaccination programmes in England and Wales: a modelling and cost-effectiveness analysis.
    Hodgson D; Baguelin M; van Leeuwen E; Panovska-Griffiths J; Ramsay M; Pebody R; Atkins KE
    Lancet Public Health; 2017 Feb; 2(2):e74-e81. PubMed ID: 28299371
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness Analysis of Maternal Immunization with RSVpreF Vaccine for the Prevention of Respiratory Syncytial Virus Among Infants in Spain.
    Álvarez Aldean J; Rivero Calle I; Rodríguez Fernández R; Aceituno Mata S; Bellmunt A; Prades M; Law AW; López-Ibáñez de Aldecoa A; Méndez C; García Somoza ML; Soto J; Lozano V
    Infect Dis Ther; 2024 Jun; 13(6):1315-1331. PubMed ID: 38733493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mathematical modelling of respiratory syncytial virus (RSV) in low- and middle-income countries: A systematic review.
    Mezei A; Cohen J; Renwick MJ; Atwell J; Portnoy A
    Epidemics; 2021 Jun; 35():100444. PubMed ID: 33662812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: A modeling study to inform policy and investment decisions.
    Laufer RS; Driscoll AJ; Baral R; Buchwald AG; Campbell JD; Coulibaly F; Diallo F; Doumbia M; Galvani AP; Haidara FC; Kotloff KL; Keita AM; Neuzil KM; Orenstein EW; Orenstein LAV; Pecenka C; Sow S; Tapia MD; Ortiz JR; Fitzpatrick MC
    Vaccine; 2021 Aug; 39(35):5037-5045. PubMed ID: 34325934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of strategies for preventing paediatric lower respiratory infections associated with respiratory syncytial virus in eight Chinese cities.
    Liu D; Leung K; Jit M; Wu JT
    Vaccine; 2021 Sep; 39(39):5490-5498. PubMed ID: 34454783
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes.
    Phijffer EW; de Bruin O; Ahmadizar F; Bont LJ; Van der Maas NA; Sturkenboom MC; Wildenbeest JG; Bloemenkamp KW
    Cochrane Database Syst Rev; 2024 May; 5(5):CD015134. PubMed ID: 38695784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial.
    Bebia Z; Reyes O; Jeanfreau R; Kantele A; De Leon RG; Sánchez MG; Banooni P; Gardener GJ; Rasero JLB; Pardilla MBE; Langley JM; Di Leo CM; Botelho-Nevers E; Buttery J; Laurichesse H; Madhi SA; García AM; Stanley T; Barjat T; Griffith R; Castrejón-Alba MM; de Heusch M; Dieussaert I; Hercor M; Lese P; Qian H; Tullio AN; Henry O
    J Infect Dis; 2023 Aug; 228(3):299-310. PubMed ID: 36722147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical impact of multiple prevention strategies for respiratory syncytial virus infections in infants and high-risk toddlers in the United States.
    Ektare V; Lang J; Choi Y; Finelli L
    Vaccine; 2022 Oct; 40(42):6064-6073. PubMed ID: 36096968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meeting report: WHO consultation on Respiratory Syncytial Virus (RSV) vaccine development, Geneva, 25-26 April 2016.
    Giersing BK; Karron RA; Vekemans J; Kaslow DC; Moorthy VS
    Vaccine; 2019 Nov; 37(50):7355-7362. PubMed ID: 28302410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Parental knowledge about respiratory syncytial virus (RSV) and attitudes to infant immunization with monoclonal antibodies.
    Lee Mortensen G; Harrod-Lui K
    Expert Rev Vaccines; 2022 Oct; 21(10):1523-1531. PubMed ID: 35929971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.